To discuss the importance of outcome measures further, pharmaphorum spoke with Sonia Bothorel, Managing Director of Mapi ...

Learn more about the summit in the Event Guide here.

Cytokinetics should hear back from the FDA next September about its marketing application for aficamten, which is vying to ...

Join us at the 2nd Peptide-Based Therapeutics Summit, where we’ll unite the leading minds in peptide science to explore the ...

The deal with Tubulis gives Gilead access to the German biotech's ADC technology platform, designed to make ADCs more stable, ...

Since the start of the year, Ipsen has bolstered its oncology pipeline with two ADC alliances – with Foreseen Bio and Sutro ...

Modern medicine moves ever more to precision, personalised medicine, and precision dosing is critical in a world that ...

The Northern Ireland Protocol (NIP) that kept NI within the EU pharma regulatory system was widely derided for failing to resolve disparities between the EU and GB pharma regulatory environment, ...

Cost-effectiveness agency NICE has recommended NHS use of the therapy, called Kimmtrak (tebentafusp), for the treatment of ...

Novartis has made a dramatic return to the Huntington's disease therapy stage by licensing a candidate from PTC Therapeutics ...

"A prerequisite for Orexo to succeed with a sophisticated digital health product like Deprexis is a tight collaboration with ...

In its complaint, BMS alleges that HHS' Health Resources and Services Administration (HRSA), which has responsibility for ...